California Health Professional Student Alliance (CaHPSA)

In our paper, we encompass the topic of socioeconomic disparities intrinsic to drug pricing and look at ways to ensure that every individual in the United States can access antibiotics equally and equitably. In the United States, a multitude of individuals find themselves struggling with high, out-of-pocket costs for necessary antibiotics or medications.  These issues are generally caused by factors surrounding monopolistic drug markets, high costs for development, and the severity of disease that an individual is facing. We explore these challenges from a plethora of perspectives, such as; the role of specialty pharmacies, limited distribution networks, and the usage of psychotropic medications among youth with Autism Spectrum Disorders (ASD). High prices and restricted access of certain antibiotics for conditions like Hepatitis C highlight the systemic and intrinsic issues within the pharmaceutical industry and how it affects individuals who suffer from this disease or diseases similar to it. On a similar topic to that, ongoing shortages of ADHD medications continue to show the consistent and heavy impact of supply constraints amongst the pharmaceutical industry in the United States. We discuss potential solutions, including but not limited to, accelerating the approval of basic drugs, implementing ceiling prices to prevent high costs, and better integrating health-system specialty pharmacies. By concentrating on the need for policy reforms within the United States and collaboration amongst the various stakeholders that remain involved with drug pricing disparities, this study aims to offer a varied approach in reducing drug pricing disparities and making necessary medications accessible to every individual in the United States, regardless of socioeconomic or health status.

As the number of incarcerated women in the United States increases, it is important to address the persistent lack of care for women’s health. Research is only beginning to be done on how the health needs of incarcerated women are equal or even greater than that of non-incarcerated women. In and out of prisons, proper reproductive care is a basic, undeniable human right to have. In this literature review, we aim to raise awareness about the current state of reproductive care in prison settings. Comprehensive reproductive care includes access to sexual health supplies, menstrual products, prenatal care, and OB-GYN appointments, which are currently almost absent or dismally deficient in prisons. When considering the population of incarcerated women, it is important to keep in mind the systemic inequalities that have already made women of these socioeconomic backgrounds more susceptible to harm due to an inability to access health insurance and higher risks for infectious diseases. Preventative medical care such as STI testing and quality menstruation products, in addition to prenatal care for expecting mothers, is severely lacking. The experiences of transgender women reveal inadequacies in structural policies and consideration for mental health. In order to reform our prison systems to become more rehabilitative, we propose implementing structural interventions that account for a comprehensive reproductive healthcare system within prisons. This includes the enforcement of stricter accreditation for physicians working in prisons, utilization of telehealth, and comprehensive sexual and reproductive care protocol.

This literature review examines the progressive issue of proliferating pharmaceutical prices, focusing on the challenges posed by off-patent, life-saving medications. We address the impact of monopolistic pricing strategies, specifically prices of medications distributed by private pharmaceutical companies, the ethical responsibility of ensuring access to necessary medicines, and the role of government regulations in the pricings of pharmaceutical products. Our paper highlights the need for effective and equitable policies to regulate pricing, including the involvement of pharmaceutical benefit managers, and the potential for reform through governmental intervention to ensure equal access to affordable medications.